Professor Kim Chang-geun of Sanggye Paik Hospital elected a director of the Asia-Pacific Allergy Asthma Clinical Immunology Society
Jan 08, 2025
Professor Kim Chang-geun of the Asthma Allergy and Clinical Immunology (APAAACI) at Inje University Sanggye Paik Hospital has been elected as a director of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology.
Professor Kim attended the APAAACI 2024 Congress International Academic Conference held in Kuala Lumpur, Malaysia from the 12th to the 15th of last month as a speaker and chair, and was elected as a director of the society on the 14th after review by the standing executive committee. The term of office is two years from 2025 to 2026.
Professor Kim presented the theme of `Eosinophils as Biomarkers in Asthma' at this conference and chaired a symposium session on the theme of"The Future of Allergy Immunology Innovation in the Age of Artificial Intelligence".
Professor Kim has been active as the chairman of the immunotherapy committee, a member of the academic committee, and a member of the publication committee at APAAACI, which boasts a history of more than 30 years, and has continued his efforts to research and treat allergy and asthma diseases at home and abroad, including serving as the 28th president of the Korean Pediatric Allergy Respiratory Society.
Professor Kim is Mayo in Rochester, Minnesota, USAA 5-year eosinophil asthma biomarker study was conducted at the clinic and the University of Wisconsin. In addition, it holds U.S. and Japanese patents for asthma allergy rapid diagnosis kits, contributing to early diagnosis of asthma and development of customized treatment methods.
Meanwhile, APAAACI is a representative conference with more than 30 years of history in allergy, asthma and clinical immunology in the Asia-Pacific region, and is scheduled to hold an international academic conference in Jakarta, Indonesia, in October 2025.
Professor Kim attended the APAAACI 2024 Congress International Academic Conference held in Kuala Lumpur, Malaysia from the 12th to the 15th of last month as a speaker and chair, and was elected as a director of the society on the 14th after review by the standing executive committee. The term of office is two years from 2025 to 2026.
Professor Kim presented the theme of `Eosinophils as Biomarkers in Asthma' at this conference and chaired a symposium session on the theme of"The Future of Allergy Immunology Innovation in the Age of Artificial Intelligence".
Professor Kim has been active as the chairman of the immunotherapy committee, a member of the academic committee, and a member of the publication committee at APAAACI, which boasts a history of more than 30 years, and has continued his efforts to research and treat allergy and asthma diseases at home and abroad, including serving as the 28th president of the Korean Pediatric Allergy Respiratory Society.
Professor Kim is Mayo in Rochester, Minnesota, USAA 5-year eosinophil asthma biomarker study was conducted at the clinic and the University of Wisconsin. In addition, it holds U.S. and Japanese patents for asthma allergy rapid diagnosis kits, contributing to early diagnosis of asthma and development of customized treatment methods.
Meanwhile, APAAACI is a representative conference with more than 30 years of history in allergy, asthma and clinical immunology in the Asia-Pacific region, and is scheduled to hold an international academic conference in Jakarta, Indonesia, in October 2025.
|
This article was translated by Naver AI translator.
